New Radiopharmaceuticals to Feature at EANM Congress
Researchers will present updated clinical trial data on potential cancer therapies at the upcoming medical conference.
Updated on Oct. 7, 2026 in Cancer
Live Poll
Will new clinical trial data presented at upcoming medical conferences significantly advance cancer treatment options?
The European Association of Nuclear Medicine Congress in Vienna, Austria, will host scientific presentations on investigational radiopharmaceuticals from October 17 to October 21, 2026. Experts will share findings from the COMPETE trial for neuroendocrine tumors and imaging agents for renal cell carcinoma.
Why it matters
These presentations provide new data on ongoing research into targeted cancer treatments and imaging diagnostics. Understanding these findings is essential for tracking the development of future therapeutic options for patients with complex solid tumors.
Researchers will present dose-response findings from the Phase 3 COMPETE trial and interim data from a retrospective analysis of the investigational PET imaging agent Ga-DPI-4452. These studies assess clinical outcomes for patients with gastroenteropancreatic neuroendocrine tumors and renal cell carcinoma.
The players
ITM
A biotechnology company focused on the development and production of radiopharmaceuticals for cancer treatment.
Lumara Bio
A life sciences organization collaborating on the presentation of oncology research data.
Actineer
A joint venture between ITM and Canadian Nuclear Laboratories focused on increasing the supply of medical radioisotopes.
Dr. Anthime Flaus
A researcher presenting clinical dose-response findings for neuroendocrine tumor therapies.
Dr. Neil Quigley
An expert focused on the manufacturing and production capacity of medical-grade Actinium-225.
The details
The presentations focus on radiopharmaceuticals that deliver targeted radiation directly to cancer cells or provide diagnostic imaging. The COMPETE trial investigates 177Lu-edotreotide, a targeted therapy designed to bind to tumor cells, while the Ga-DPI-4452 analysis examines a tracer for identifying clear cell renal cell carcinoma. Experts will also discuss strategies to increase global production capacity for Actinium-225, a radioisotope used in advanced oncology research.
Timeline
The EANM Congress takes place in Vienna from October 17 to October 21, 2026.
Dr. Alina Küper presents Ga-DPI-4452 interim results on October 18, 2026, at 15:00 CEST.
Dr. Neil Quigley shares Actinium-225 production insights on October 19, 2026, at 10:30 CEST.
Dr. Anthime Flaus presents COMPETE trial findings on October 20, 2026, at 15:00 CEST.
Health Landscape
The development of these radiopharmaceuticals marks a shift toward more precise, targeted molecular cancer therapies. These clinical updates provide critical data that helps determine how such investigational drugs may eventually integrate into standard oncology protocols.
These updates involve drugs that are currently in clinical trials and are not yet available for patient use outside of approved research settings. If you are managing a neuroendocrine or renal condition, discuss the current status of these clinical trials with your oncologist to understand if future studies might be relevant.
The takeaway
These findings represent ongoing progress in the field of nuclear medicine as researchers aim to improve both diagnostic accuracy and treatment survival. Keep track of updates from major oncology conferences to learn when new therapeutic options move closer to clinical application.
Further reading
For broader context on clinical research in oncology, visit our Cancer section.
Live Poll
Will new clinical trial data presented at upcoming medical conferences significantly advance cancer treatment options?
